GlassScriptPhysician profile
Mary M Daniel
NPI 1073836466
$5,263.21
in general payments reported to CMS, 2019-2025
34 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $739 · 2022: $988 · 2023: $1,242 · 2024: $1,043 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $613.54 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $549.16 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $469.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $415.45 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $390.99 | 2021-2025 | |
| Amgen INC. | $264.98 | 2021-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $174.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.73 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $119.00 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Dynavax Technologies Corporation | $100.57 | 2024-2025 | Heplisav-B |
| Supernus Pharmaceuticals, INC. | $84.11 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $80.60 | 2024-2025 | Voquezna |
| Abbott Laboratories | $67.65 | 2022-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $63.77 | 2022-2024 | Veozah |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.